 |
|
|
| |
Integrated Analysis of Sofosbuvir
+Ribavirin, Ledipasvir/Sofosbuvir or Sofosbuvir/Velpatasvir for the Treatment of Genotype 4 Chronic HCV Infection
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Tarik Asselah7, Gamal Shiha5, Jordan J. Feld3, Armand Abergel6, Anita Kohli2, Shyam Kottilil9, Susanna Naggie8, Cathleen Letterio1, Thomas A. Hahambis1, Joseph Llewellyn1, Macky Natha1, Kathryn Kersey1, John McNally1, Diana M. Brainard1, Gamal E. Esmat10, Peter J. Ruane4
1Gilead Sciences, Foster City, CA, United States. 2 Creighton University School of Medicine, Phoenix, AZ, United States. 3. Toronto Western Hospital, Toronto, ON, Canada. 4. Ruane Medical and Liver Health Institute, Los Angeles, CA, United States. 5. Egyptian Liver Research Institute and Hospital, Egypt. 6. Beaujon Hospital, Clermont Ferrand, France. 7. Service d'Hepatologie & INSERM U773 CRB3, Hôpital Beaujon, Clichy, France. 8. Duke Clinical Research Institute, Durham, NC, United States. 9. NIAID, Baltimore, MD, United States. 10. Cairo University, Cairo, Egypt.
|
| |
|
|
|
|
|
